Filing Flows › Biomerica (BMRA) › Q2 FY26
Biomerica (BMRA) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Jan 14, 2026
Biomerica (BMRA) reported revenue of $1.2M for the second quarter fiscal 2026 (Q2 FY26), -26% from a year earlier and -12% from the quarter before. Operating margin was -113.5%, net loss $1.3M (109.1% of revenue).
Biomerica, Q2 FY26: revenue $1.2M (-26% year over year), operating margin -113.5%, net loss $1.3M, operating cash flow −$991K. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | -12% | -26% |
| Operating profit | −$1.4M | — | — |
| Net earnings | −$1.3M | -66100% | — |
| Operating cash flow | −$991K | — | — |
What changed
Revenue was $1.2M in Q2 FY26, down 26% year over year and down 12% from the previous quarter. Clinical Lab was the largest line at 56% of revenue. Over -the-Counter lost $235K year over year (down 39%), 55% of the total change.
Gross margin was 4.2%, down 22.5 points from a year earlier. Operating costs exceeded revenue by $1.4M, an operating margin of -113.5%. Operating expenses fell 0% while revenue fell 26%. The quarter ended with a net loss of $1.3M, after a profit of $2K the previous quarter.
Operating cash flow was −$1.0M. Non-cash charges added back $20K of depreciation and amortization and $117K of share-based compensation. Working capital and other items added $192K.
Questions
What was Biomerica's revenue in the second quarter fiscal 2026?
Biomerica (BMRA) reported revenue of $1.2M for the second quarter fiscal 2026 (Q2 FY26), -26% from a year earlier and -12% from the quarter before.
Was Biomerica profitable in the second quarter fiscal 2026?
Operating loss was $1.4M (-113.5% of revenue) and net loss $1.3M.
Source: Biomerica 10-Q on SEC EDGAR.